This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...

Vertex Pharmaceuticals' strategy is to develop medicines in areas with high unmet needs. The company has dominated the market for cystic fibrosis (CF) -- a rare disease that affects internal organs -- ...

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, both citing confidence in the company’s core cystic fibrosis business and ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Nov 3 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. VERX offers steady low-teens growth, expanding margins, and a sticky tax compliance software ...

Vertex Pharmaceuticals remains a buy, anchored by its dominant cystic fibrosis (CF) franchise and optionality in JOURNAVX. VRTX's near-term growth hinges on JOURNAVX's commercial ramp and pivotal ...

Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...